Jason Raleigh Nunn - 09 Oct 2025 Form 4 Insider Report for Zenas BioPharma, Inc. (ZBIO)

Reporting relationship: Director
Issuer ticker: ZBIO
Reported as of: 09 Oct 2025
Net transaction value: +$1,200,002
SEC form: 4
Accepted by SEC: 14 Oct 2025, 17:16:29 UTC
Prior SEC filing: 27 Jun 2025
Next SEC filing: 18 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Sasha Keough, attorney-in-fact for Jason R. Nunn

Filing notes and source

Key filing fact

Jason Raleigh Nunn filed Form 4 for Zenas BioPharma, Inc. (ZBIO) on 14 Oct 2025.

Key facts

This page summarizes Jason Raleigh Nunn's Form 4 filing for Zenas BioPharma, Inc. (ZBIO).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 14 Oct 2025, 17:16.

Change

Previous filing in this sequence was filed on 27 Jun 2025.
Current net transaction value: +$1,200,002.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001444319 Primary reporting owner

Nunn Jason Raleigh

Relationship: Director
Address: 985 OLD EAGLE SCHOOL ROAD, SUITE 511, WAYNE
Signature: /s/ Sasha Keough, attorney-in-fact for Jason R. Nunn
Signature date: 14 Oct 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ZBIO transaction

Common Stock

Purchase

Transaction value: $1,200,002
Shares: +63,158
Change %: +5.7%
Price: $19.00
Shares after: 1,173,395
Date: 09 Oct 2025
Ownership: See Note 2
Footnotes: F1, F2

ZBIO holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,946,564
Date: 09 Oct 2025
Ownership: See Note 3
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Acquired from the Issuer on October 9, 2025 pursuant to a Securities Purchase Agreement dated October 7, 2025.

Footnote F2

The reported securities are held directly by SR One Capital Opportunities Fund I, LP. SR One Capital Opportunities Partners I, LP is the general partner of SR One Capital Opportunities Fund I, LP. The Reporting Person is a partner of SR One Capital Management, LP, an entity affiliated with SR One Capital Opportunities Fund I, LP, and a limited partner of SR One Capital Opportunities Partners I, LP. The Reporting Person disclaims beneficial ownership of these securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended ("Section 16"), except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for Section 16 or any other purpose.

Footnote F3

The reported securities are held directly by SR One Capital Fund II Aggregator, LP. SR One Capital Partners II, LP is the general partner of SR One Capital Fund II Aggregator, LP. The Reporting Person is a partner of SR One Capital Management, LP, an entity affiliated with SR One Capital Fund II Aggregator, LP, and a limited partner of SR One Capital Partners II, LP. The Reporting Person disclaims beneficial ownership of these securities for purposes of Section 16, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for Section 16 or any other purpose.